Medicus Pharma (MDCX) Cash from Financing Activities (2024 - 2025)

Medicus Pharma (MDCX) posted Cash from Financing Activities of $6.7 million for Q4 2025, down 35.85% quarter-over-quarter from $10.4 million in Q3 2025, and up 224.6% year-on-year from $2.0 million in Q4 2024.

Medicus Pharma (MDCX) Cash from Financing Activities (2024 - 2025) Analysis & Trends

Medicus Pharma (MDCX) has reported Cash from Financing Activities for 2 consecutive years, with $6.7 million the latest figure, recorded in Q4 2025.

  • Cash from Financing Activities for Q4 2025 came in at $6.7 million, up 224.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $31.9 million (up 151.65% YoY), and the FY2025 annual result was $31.9 million, up 151.65% from the prior year.
  • Cash from Financing Activities was $6.7 million for Q4 2025 at Medicus Pharma, down from $10.4 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $11.2 million in Q2 2025 and troughed at $2.0 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -3.47 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 530.00 Mn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 919.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 267.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -2.98 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.44 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -4.24 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -2.86 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Medicus Pharma 6.91 Mn -1.69 Mn - 6.65 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 6.65 Mn
Dec 31, 2025 6.65 Mn
Sep 30, 2025 10.37 Mn
Sep 30, 2025 10.37 Mn
Jun 30, 2025 11.16 Mn
Jun 30, 2025 11.16 Mn
Mar 31, 2025 3.76 Mn
Mar 31, 2025 3.76 Mn
Dec 31, 2024 2.05 Mn
Dec 31, 2024 2.05 Mn
Jun 30, 2024 10.64 Mn
Jun 30, 2024 10.64 Mn